102130-43-8
Chemical Structure
Atractyloside potassium salt
- CAS No.: 102130-43-8
- Formula:C30H44K2O16S2
- Molecular Weight:802.99
IUPAC Name: potassium (2R,3R,4R,5R,6R)-6-(((2R,4aR,6aR,7S,9R,11aS,11bR)-4-carboxy-7-hydroxy-11b-methyl-8-methylenetetradecahydro-6a,9-methanocyclohepta[a]naphthalen-2-yl)oxy)-2-(hydroxymethyl)-5-((3-methylbutanoyl)oxy)tetrahydro-2H-pyran-3,4-diyl bis(sulfate)
InChIKey: IUCNQFHEWLYECJ-LNCQVOIYSA-L
SMILES: [H][C@@]12C(C(O)=O)C[C@@H](O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)OS(=O)(O[K])=O)OS(=O)(O[K])=O)OC(CC(C)C)=O)C[C@@]1(C)[C@@]4([H])[C@@]5([C@@H](O)C([C@H](CC4)C5)=C)CC2
Biological Activity: Atractyloside potassium salt is a powerful and specific inhibitor of mitochondrial ADP/ATP transport. Atractyloside potassium salt inhibits chloride channels from mitochondrial membranes of rat heart. Atractyloside potassium salt activates autophagy, inhibits ANT2, mTOR and promotes the activation of p-AMPK. Atractyloside potassium salt has anti-cancer effects on non-small cell lung cancer and can inhibit liver steatosis. Atractylodesin potassium salt has nephrotoxicity[1][2][3][4][5][6][7][8][9][10][11][12][13][14].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Atractyloside potassium salt | 99.93% | Atractyloside potassium salt is a powerful and specific inhibitor of mitochondrial ADP/ATP transport. Atractyloside potassium salt inhibits chloride channels from mitochondrial membranes of rat heart. Atractyloside potassium salt activates autophagy, inhibits ANT2, mTOR and promotes the activation of p-AMPK. Atractyloside potassium salt has anti-cancer effects on non-small cell lung cancer and can inhibit liver steatosis. Atractylodesin potassium salt has nephrotoxicity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Atractyloside potassium salt (Standard) | ≥98% | Atractyloside (potassium salt) (Standard) is the analytical standard of Atractyloside (potassium salt). This product is intended for use in research and analytical applications. Atractyloside potassium salt is a powerful and specific inhibitor of mitochondrial ADP/ATP transport. Atractyloside potassium salt inhibits chloride channels from mitochondrial membranes of rat heart. Atractyloside potassium salt activates autophagy, inhibits ANT2, mTOR and promotes the activation of p-AMPK. Atractyloside potassium salt has anti-cancer effects on non-small cell lung cancer and can inhibit liver steatosis. Atractylodesin potassium salt has nephrotoxicity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Malekova L, et al. Bongkrekic acid and atractyloside inhibits chloride channels from mitochondrial membranes of rat heart. Biochim Biophys Acta. 2007 Jan;1767(1):31-44. [Content Brief]
- [2]. Nikles S, et al. Influence of Processing on the Content of Toxic Carboxyatractyloside and Atractyloside and the Microbiological Status of Xanthium sibiricum Fruits (Cang'erzi). Planta Med. 2015 Aug;81(12-13):1213-20. [Content Brief]
- [3]. Lemasters JJ, et al. Phosphate dependence and atractyloside inhibition of mitochondrial oxidative phosphorylation. The ADP-ATP carrier is rate-limiting. J Biol Chem. 1979 Feb 25;254(4):1248-51. [Content Brief]
- [4]. Malekova L, et al. Bongkrekic acid and atractyloside inhibits chloride channels from mitochondrial membranes of rat heart. Biochim Biophys Acta. 2007 Jan;1767(1):31-44.
- [5]. Song R, et al. Atractyloside induces low contractile reaction of arteriolar smooth muscle through mitochondrial damage. J Appl Toxicol. 2012 Jun;32(6):402-8. [Content Brief]
- [6]. Zhang P, et al. Mitochondrial Energy-Regulating Effect of Atractyloside Inhibits Hepatocellular Steatosis Through the Activation of Autophagy. Front Pharmacol. 2020 Sep 30;11:575695. [Content Brief]
- [7]. Capasso JM, et al. Effect of atractylosides, palmitoyl coenzyme A, and anion transport inhibitors on translocation of nucleotide sugars and nucleotide sulfate into Golgi vesicles. J Biol Chem. 1984 Apr 10;259(7):4263-6. [Content Brief]
- [8]. Obatomi DK, et al. Selective cytotoxicity associated with in vitro exposure of fresh rat renal fragments and continuous cell lines to atractyloside. Arch Toxicol. 1996;71(1-2):93-8. [Content Brief]
- [9]. Obatomi DK, et al. The toxic mechanism and metabolic effects of atractyloside in precision-cut pig kidney and liver slices. Arch Toxicol. 1998 Jul-Aug;72(8):524-30. [Content Brief]
- [10]. Yao W, et al. Atractyloside inhibits gefitinib‑resistant non‑small‑cell lung cancer cell proliferation. Oncol Lett. 2024 Jul 30;28(4):466. [Content Brief]
- [11]. Vancompernolle K, et al. Atractyloside-induced release of cathepsin B, a protease with caspase-processing activity. FEBS Lett. 1998 Nov 6;438(3):150-8. [Content Brief]
- [12]. Gao Q, et al. Atractyloside and 5-hydroxydecanoate block the protective effect of puerarin in isolated rat heart. Life Sci. 2006 Jun 13;79(3):217-24. [Content Brief]
- [13]. Zhang P, et al. Atractyloside Protect Mice Against Liver Steatosis by Activation of Autophagy via ANT-AMPK-mTORC1 Signaling Pathway. Front Pharmacol. 2021 Sep 21;12:736655. [Content Brief]
- [14]. Carpenedo F, et al. Nephrotoxic effect of atractyloside in rats. Arch Toxicol. 1974;32(3):169-80. [Content Brief]
